625 results on '"Fondation ARC"'
Search Results
2. A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer (ABLE02)
- Author
-
Fondation ARC and Janssen, LP
- Published
- 2024
3. Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)
- Author
-
National Cancer Institute, France, Fondation ARC, and Hoffmann-La Roche
- Published
- 2024
4. Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO)
- Author
-
National Cancer Institute, France, Fondation ARC, and Novartis
- Published
- 2024
5. 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
- Author
-
Fondation ARC
- Published
- 2024
6. Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)
- Author
-
National Cancer Institute, France, Fondation ARC, and Pfizer
- Published
- 2024
7. Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq)
- Author
-
Merck Sharp & Dohme LLC, Fondation ARC, and ERA-NET
- Published
- 2024
8. Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (CHECK'UP)
- Author
-
Fondation ARC
- Published
- 2024
9. SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)
- Author
-
Fondation ARC and AstraZeneca
- Published
- 2024
10. SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)
- Author
-
Intergroupe Francophone de Cancerologie Thoracique, Fondation ARC, and AstraZeneca
- Published
- 2024
11. Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
- Author
-
Hôpital Necker-Enfants Malades, Fondation ARC, Pfizer, and Takeda
- Published
- 2023
12. Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)
- Author
-
Bristol-Myers Squibb and Fondation ARC
- Published
- 2023
13. Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer (DISCO)
- Author
-
Fondation ARC, National Cancer Institute, France, Fondation pour la Recherche Médicale, Cancéropôle Lyon Auvergne Rhône-Alpes, and AG2R La Mondiale
- Published
- 2023
14. Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (SAFIR-TOR)
- Author
-
Novartis and Fondation ARC
- Published
- 2022
15. Early Screening of Pancreatic Lesions : Development of New Imaging Tools (PAIR-PANCREAS)
- Author
-
National Cancer Institute, France, Ligue contre le cancer, France, and Fondation ARC
- Published
- 2022
16. A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)
- Author
-
National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, and Transgene
- Published
- 2022
17. A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (RUBY)
- Author
-
Clovis Oncology, Inc. and Fondation ARC
- Published
- 2021
18. Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (PIK-ORL)
- Author
-
National Cancer Institute, France and Fondation ARC
- Published
- 2019
19. PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
- Author
-
Fondation ARC and National Cancer Institute, France
- Published
- 2019
20. Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs (TOPTACOS)
- Author
-
University of Angers, GRANEM and Fondation ARC
- Published
- 2018
21. R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
- Author
-
Fondation ARC
- Published
- 2018
22. ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
- Author
-
Fondation ARC
- Published
- 2007
23. Changes in Liver Lipidomic Profile in G2019S- LRRK2 Mouse Model of Parkinson's Disease
- Author
-
Instituto de Salud Carlos III, European Commission, Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, Ministerio de Economía y Competitividad (España), Ministerio de Cultura y Deporte (España), Universidad de Extremadura, Junta de Extremadura, Ligue Nationale contre le Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, Cancéropôle Île-de-France, Chancellerie des Universités de Paris, Fondation pour la Recherche Médicale, European Research Area Network on Cardiovascular Diseases, European Research Council, Pérez-Tur, Jordi [0000-0002-9111-1712], Corral Nieto, Yaiza, Yakhine-Diop, Sokhna M. S., Moreno-Cruz, Paula, Manrique García, Laura, Gabrielly Pereira, Amanda, Morales-García, José A., Niso-Santano, Mireia, González-Polo, Rosa A., Uribe-Carretero, Elisabet, Durand, Sylvère, Maiuri, Maria Chiara, Paredes-Barquero, Marta, Alegre-Cortés, Eva, Canales-Cortés, Saray, López de Munain, Adolfo, Pérez-Tur, Jordi, Pérez-Castillo, Ana, Kroemer, Guido, Fuentes, José M., Bravo-San-Pedro, José Manuel, Instituto de Salud Carlos III, European Commission, Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, Ministerio de Economía y Competitividad (España), Ministerio de Cultura y Deporte (España), Universidad de Extremadura, Junta de Extremadura, Ligue Nationale contre le Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, Cancéropôle Île-de-France, Chancellerie des Universités de Paris, Fondation pour la Recherche Médicale, European Research Area Network on Cardiovascular Diseases, European Research Council, Pérez-Tur, Jordi [0000-0002-9111-1712], Corral Nieto, Yaiza, Yakhine-Diop, Sokhna M. S., Moreno-Cruz, Paula, Manrique García, Laura, Gabrielly Pereira, Amanda, Morales-García, José A., Niso-Santano, Mireia, González-Polo, Rosa A., Uribe-Carretero, Elisabet, Durand, Sylvère, Maiuri, Maria Chiara, Paredes-Barquero, Marta, Alegre-Cortés, Eva, Canales-Cortés, Saray, López de Munain, Adolfo, Pérez-Tur, Jordi, Pérez-Castillo, Ana, Kroemer, Guido, Fuentes, José M., and Bravo-San-Pedro, José Manuel
- Abstract
The identification of Parkinson's disease (PD) biomarkers has become a main goal for the diagnosis of this neurodegenerative disorder. PD has not only been intrinsically related to neurological problems, but also to a series of alterations in peripheral metabolism. The purpose of this study was to identify metabolic changes in the liver in mouse models of PD with the scope of finding new peripheral biomarkers for PD diagnosis. To achieve this goal, we used mass spectrometry technology to determine the complete metabolomic profile of liver and striatal tissue samples from WT mice, 6-hydroxydopamine-treated mice (idiopathic model) and mice affected by the G2019S-LRRK2 mutation in LRRK2/PARK8 gene (genetic model). This analysis revealed that the metabolism of carbohydrates, nucleotides and nucleosides was similarly altered in the liver from the two PD mouse models. However, long-chain fatty acids, phosphatidylcholine and other related lipid metabolites were only altered in hepatocytes from G2019S-LRRK2 mice. In summary, these results reveal specific differences, mainly in lipid metabolism, between idiopathic and genetic PD models in peripheral tissues and open up new possibilities to better understand the etiology of this neurological disorder.
- Published
- 2023
24. Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence
- Author
-
Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), CSIC-UVA - Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León, Ministerio de Universidades (España), Ligue Nationale contre le Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, European Research Council, Fondation pour la Recherche Médicale, Institut National du Cancer (France), Institut Universitaire de France, Université de Paris, Universidad de Valladolid, Barriuso, Daniel, Álvarez-Frutos, Lucía, González-Gutiérrez, Lucía, Motiño, Omar, Kroemer, Guido, Palacios-Ramírez, Roberto, Senovilla, Laura, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), CSIC-UVA - Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León, Ministerio de Universidades (España), Ligue Nationale contre le Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, European Research Council, Fondation pour la Recherche Médicale, Institut National du Cancer (France), Institut Universitaire de France, Université de Paris, Universidad de Valladolid, Barriuso, Daniel, Álvarez-Frutos, Lucía, González-Gutiérrez, Lucía, Motiño, Omar, Kroemer, Guido, Palacios-Ramírez, Roberto, and Senovilla, Laura
- Abstract
The B-cell lymphoma 2 (Bcl-2) family of proteins is the main regulator of apoptosis. However, multiple emerging evidence has revealed that Bcl-2 family proteins are also involved in cellular senescence. On the one hand, the different expression of these proteins determines the entry into senescence. On the other hand, entry into senescence modulates the expression of these proteins, generally conferring resistance to apoptosis. With some exceptions, senescent cells are characterized by the upregulation of antiapoptotic proteins and downregulation of proapoptotic proteins. Under physiological conditions, freshly formed tetraploid cells die by apoptosis due to the tetraploidy checkpoint. However, suppression of Bcl-2 associated x protein (Bax), as well as overexpression of Bcl-2, favors the appearance and survival of tetraploid cells. Furthermore, it is noteworthy that our laboratory has shown that the joint absence of Bax and Bcl-2 antagonist/killer (Bak) favors the entry into senescence of tetraploid cells. Certain microtubule inhibitory chemotherapies, such as taxanes and vinca alkaloids, induce the generation of tetraploid cells. Moreover, the combined use of inhibitors of antiapoptotic proteins of the Bcl-2 family with microtubule inhibitors increases their efficacy. In this review, we aim to shed light on the involvement of the Bcl-2 family of proteins in the senescence program activated after tetraploidization and the possibility of using this knowledge to create a new therapeutic strategy targeting cancer cells.
- Published
- 2023
25. Quantitative analysis of protein-RNA interactions in fission yeast
- Author
-
Universidad de Sevilla. Departamento de Genética, Fondation pour la Recherche Médicale, Biotechnology and Biological Sciences Research Council (BBSRC), Agence Nationale de la Recherche. France, Fondation ARC pour la recherche sur le cancer, Elías Villalobos, Alberto, Duncan, Caia, Mata, Juan, Helmlinger, Dominique, Universidad de Sevilla. Departamento de Genética, Fondation pour la Recherche Médicale, Biotechnology and Biological Sciences Research Council (BBSRC), Agence Nationale de la Recherche. France, Fondation ARC pour la recherche sur le cancer, Elías Villalobos, Alberto, Duncan, Caia, Mata, Juan, and Helmlinger, Dominique
- Abstract
Characterizing the interactions between RNAs and proteins in vivo is key to better understand how organisms regulate gene expression. Here, we describe a robust and quantitative protocol to measure specific RNA-protein interactions in a native context using RNA immunoprecipitation (RIP). We provide a comprehensive experimental framework to detect cotranslational interactions and detail the quantitative analysis of purified RNAs by PCR and high-throughput sequencing. Although we developed the protocol in fission yeast, it can be readily implemented in other yeast species. For complete details on the use and execution of this protocol, please refer to Toullec et al. (2021).
- Published
- 2022
26. Quantitative analysis of protein-RNA interactions in fission yeast
- Author
-
Fondation pour la Recherche Médicale, European Commission, Universidad de Sevilla, Biotechnology and Biological Sciences Research Council (UK), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, Elías-Villalobos, Alberto, Duncan, Caia, Mata, Juan, Helmlinger, Dominique, Fondation pour la Recherche Médicale, European Commission, Universidad de Sevilla, Biotechnology and Biological Sciences Research Council (UK), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, Elías-Villalobos, Alberto, Duncan, Caia, Mata, Juan, and Helmlinger, Dominique
- Abstract
Characterizing the interactions between RNAs and proteins in vivo is key to better understand how organisms regulate gene expression. Here, we describe a robust and quantitative protocol to measure specific RNA-protein interactions in a native context using RNA immunoprecipitation (RIP). We provide a comprehensive experimental framework to detect cotranslational interactions and detail the quantitative analysis of purified RNAs by PCR and high-throughput sequencing. Although we developed the protocol in fission yeast, it can be readily implemented in other yeast species. For complete details on the use and execution of this protocol, please refer to Toullec et al. (2021).
- Published
- 2022
27. Enhanced wild-Type mET Receptor levels in mouse hepatocytes attenuates insulin-mediated signaling
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Comunidad de Madrid, Fundación Ramón Areces, Instituto de Salud Carlos III, Institut National du Cancer (France), Aix-Marseille Université, Fondation de France, Fondation ARC pour la Recherche sur le Cancer, Rada, Patricia, Lamballe, Fabienne, Cárcer, Guillermo de, Carceller-López, Elena, Hitos, Ana B., Sequera, Celia, Maina, Flavio, Valverde, Ángela M., Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Comunidad de Madrid, Fundación Ramón Areces, Instituto de Salud Carlos III, Institut National du Cancer (France), Aix-Marseille Université, Fondation de France, Fondation ARC pour la Recherche sur le Cancer, Rada, Patricia, Lamballe, Fabienne, Cárcer, Guillermo de, Carceller-López, Elena, Hitos, Ana B., Sequera, Celia, Maina, Flavio, and Valverde, Ángela M.
- Abstract
Compelling evidence points to the MET receptor tyrosine kinase as a key player during liver development and regeneration. Recently, a role of MET in the pathophysiology of insulin resistance and obesity is emerging. Herein, we aimed to determine whether MET regulates hepatic insulin sensitivity. To achieve this, mice in which the expression of wild-type MET in hepatocytes is slightly enhanced above endogenous levels (Alb-R26Met mice) were analyzed to document glucose homeostasis, energy balance, and insulin signaling in hepatocytes. We found that Alb-R26Met mice exhibited higher body weight and food intake when compared to R26stopMet control mice. Metabolic analyses revealed that Alb-R26Met mice presented age-related glucose and pyruvate intolerance in comparison to R26stopMet controls. Additionally, in Alb-R26Met mice, high MET levels decreased insulin-induced insulin receptor (IR) and AKT phosphorylation compared to control mice. These results were corroborated in vitro by analyzing IR and AKT phosphorylation in primary mouse hepatocytes from Alb-R26Met and R26stopMet mice upon insulin stimulation. Moreover, co-immunoprecipitation assays revealed MET-IR interaction under both basal and insulin stimulation conditions; this effect was enhanced in Alb-R26Met hepatocytes. Altogether, our results indicate that enhanced MET levels alter hepatic glucose homeostasis, which can be an early event for subsequent liver pathologies.
- Published
- 2022
28. Telomeric C-circles localize at nuclear pore complexes in Saccharomyces cerevisiae
- Author
-
Conseil Régional Provence-Alpes-Côte d'Azur, Fondation ARC pour la Recherche sur le Cancer, Agence Nationale de la Recherche (France), Ligue Nationale contre le Cancer (France), Aguilera, Paula, Dubarry, Marion, Hardy, Julien, Lisby, Michael, Simon, Marie-Noelle, Geli, Vicent, Conseil Régional Provence-Alpes-Côte d'Azur, Fondation ARC pour la Recherche sur le Cancer, Agence Nationale de la Recherche (France), Ligue Nationale contre le Cancer (France), Aguilera, Paula, Dubarry, Marion, Hardy, Julien, Lisby, Michael, Simon, Marie-Noelle, and Geli, Vicent
- Abstract
As in human cells, yeast telomeres can be maintained in cells lacking telomerase activity by recombination-based mechanisms known as ALT (Alternative Lengthening of Telomeres). A hallmark of ALT human cancer cells are extrachromosomal telomeric DNA elements called C-circles, whose origin and function have remained unclear. Here, we show that extrachromosomal telomeric C-circles in yeast can be detected shortly after senescence crisis and concomitantly with the production of survivors arising from “type II” recombination events. We uncover that C-circles bind to the nuclear pore complex (NPC) and to the SAGA-TREX2 complex, similar to other non-centromeric episomal DNA. Disrupting the integrity of the SAGA/TREX2 complex affects both C-circle binding to NPCs and type II telomere recombination, suggesting that NPC tethering of C-circles facilitates formation and/or propagation of the long telomere repeats characteristic of type II survivors. Furthermore, we find that disruption of the nuclear diffusion barrier impairs type II recombination. These results support a model in which concentration of C-circles at NPCs benefits type II telomere recombination, highlighting the importance of spatial coordination in ALT-type mechanisms of telomere maintenance.
- Published
- 2022
29. Smaug1 membrane-less organelles respond to AMPK and mTOR and affect mitochondrial function
- Author
-
Agencia Nacional de Promoción Científica y Tecnológica (Argentina), Consejo Nacional de Investigaciones Científicas y Técnicas (Argentina), Université Paris Diderot, Ministerio de Ciencia, Tecnología e Innovación Productiva (Argentina), Fondation ARC pour la Recherche sur le Cancer, Ministerio de Economía, Industria y Competitividad (España), Generalitat Valenciana, Fernández-Alvarez, Ana Julia, Thomas, Marıa Gabriela, Pascual, Malena L., Habif, Martın, Pimentel, Jerónimo, Corbat, Agustın A., Pessoa, Joao P., La Spina, Pablo E., Boscaglia, Lara, Plessis, Anne, Carmo-Fonseca, Maria, Grecco, Hernán E., Casado, Marta, Boccaccio, Graciela L., Agencia Nacional de Promoción Científica y Tecnológica (Argentina), Consejo Nacional de Investigaciones Científicas y Técnicas (Argentina), Université Paris Diderot, Ministerio de Ciencia, Tecnología e Innovación Productiva (Argentina), Fondation ARC pour la Recherche sur le Cancer, Ministerio de Economía, Industria y Competitividad (España), Generalitat Valenciana, Fernández-Alvarez, Ana Julia, Thomas, Marıa Gabriela, Pascual, Malena L., Habif, Martın, Pimentel, Jerónimo, Corbat, Agustın A., Pessoa, Joao P., La Spina, Pablo E., Boscaglia, Lara, Plessis, Anne, Carmo-Fonseca, Maria, Grecco, Hernán E., Casado, Marta, and Boccaccio, Graciela L.
- Abstract
Smaug is a conserved translational regulator that binds numerous mRNAs, including nuclear transcripts that encode mitochondrial enzymes. Smaug orthologs form cytosolic membrane-less organelles (MLOs) in several organisms and cell types. We have performed single-molecule fluorescence in situ hybridization (FISH) assays that revealed that SDHB and UQCRC1 mRNAs associate with Smaug1 bodies in U2OS cells. Loss of function of Smaug1 and Smaug2 (also known as SAMD4A and SAMD4B, respectively) affected both mitochondrial respiration and morphology of the mitochondrial network. Phenotype rescue by Smaug1 transfection depends on the presence of its RNA-binding domain. Moreover, we identified specific Smaug1 domains involved in MLO formation, and found that impaired Smaug1 MLO condensation correlates with mitochondrial defects. Mitochondrial complex I inhibition upon exposure to rotenone, but not strong mitochondrial uncoupling upon exposure to CCCP, rapidly induced the dissolution of Smaug1 MLOs. Metformin and rapamycin elicited similar effects, which were blocked by pharmacological inhibition of AMP-activated protein kinase (AMPK). Finally, we found that Smaug1 MLO dissolution weakens the interaction with target mRNAs, thus enabling their release. We propose that mitochondrial respiration and the AMPK-mTOR balance controls the condensation and dissolution of Smaug1 MLOs, thus regulating nuclear mRNAs that encode key mitochondrial proteins. This article has an associated First Person interview with the first authors of the paper.
- Published
- 2022
30. Cilia, ciliopathies and hedgehog-related forebrain developmental disorders
- Author
-
Fondation ARC pour la Recherche sur le Cancer, Fondation pour la Recherche Médicale, Andreu-Cervera, Abraham, Catala, Martin, Schneider-Maunoury, Sylvie, Fondation ARC pour la Recherche sur le Cancer, Fondation pour la Recherche Médicale, Andreu-Cervera, Abraham, Catala, Martin, and Schneider-Maunoury, Sylvie
- Abstract
Development of the forebrain critically depends on the Sonic Hedgehog (Shh) signaling pathway, as illustrated in humans by the frequent perturbation of this pathway in holoprosencephaly, a condition defined as a defect in the formation of midline structures of the forebrain and face. The Shh pathway requires functional primary cilia, microtubule-based organelles present on virtually every cell and acting as cellular antennae to receive and transduce diverse chemical, mechanical or light signals. The dysfunction of cilia in humans leads to inherited diseases called ciliopathies, which often affect many organs and show diverse manifestations including forebrain malformations for the most severe forms. The purpose of this review is to provide the reader with a framework to understand the developmental origin of the forebrain defects observed in severe ciliopathies with respect to perturbations of the Shh pathway. We propose that many of these defects can be interpreted as an imbalance in the ratio of activator to repressor forms of the Gli transcription factors, which are effectors of the Shh pathway. We also discuss the complexity of ciliopathies and their relationships with forebrain disorders such as holoprosencephaly or malformations of cortical development, and emphasize the need for a closer examination of forebrain defects in ciliopathies, not only through the lens of animal models but also taking advantage of the increasing potential of the research on human tissues and organoids.
- Published
- 2021
31. Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia
- Author
-
Agencia Estatal de Investigación (España), European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Institut National de la Santé et de la Recherche Médicale (France), Ligue Nationale contre le Cancer (France), Université de Bordeaux, Fondation pour la Recherche Médicale, Conseil régional d'Aquitaine, Fondation ARC pour la Recherche sur le Cancer, Fonds de la Recherche Scientifique (Fédération Wallonie-Bruxelles), Nguyen, Tra Ly, Nokin, Marie-Julie, Terés, Silvia, Tomé, Mercedes, Bodineau, Clément, Galmar, Oriane, Pasquet, Jean-Max, Rousseau, Benoit, Liempd, Sebastian van, Falcón-Pérez, Juan M., Richard, Elodie, Muzotte, Elodie, Rezvani, Hamid-Reza, Priault, Muriel, Bouchecareilh, Marlon, Redonnet-Vernhet, Isabelle, Calvo, Julien, Uzan, Benjamin, Pflumio, Françoise, Fuentes, Patricia, Toribio, María Luisa, Khatib, Abdel-Majid, Soubeyran, Pierre, Murdoch, Piedad del S., Durán, Raúl V., Agencia Estatal de Investigación (España), European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Institut National de la Santé et de la Recherche Médicale (France), Ligue Nationale contre le Cancer (France), Université de Bordeaux, Fondation pour la Recherche Médicale, Conseil régional d'Aquitaine, Fondation ARC pour la Recherche sur le Cancer, Fonds de la Recherche Scientifique (Fédération Wallonie-Bruxelles), Nguyen, Tra Ly, Nokin, Marie-Julie, Terés, Silvia, Tomé, Mercedes, Bodineau, Clément, Galmar, Oriane, Pasquet, Jean-Max, Rousseau, Benoit, Liempd, Sebastian van, Falcón-Pérez, Juan M., Richard, Elodie, Muzotte, Elodie, Rezvani, Hamid-Reza, Priault, Muriel, Bouchecareilh, Marlon, Redonnet-Vernhet, Isabelle, Calvo, Julien, Uzan, Benjamin, Pflumio, Françoise, Fuentes, Patricia, Toribio, María Luisa, Khatib, Abdel-Majid, Soubeyran, Pierre, Murdoch, Piedad del S., and Durán, Raúl V.
- Abstract
The cellular receptor Notch1 is a central regulator of T-cell development, and as a consequence, Notch1 pathway appears upregulated in > 65% of the cases of T-cell acute lymphoblastic leukemia (T-ALL). However, strategies targeting Notch1 signaling render only modest results in the clinic due to treatment resistance and severe side effects. While many investigations reported the different aspects of tumor cell growth and leukemia progression controlled by Notch1, less is known regarding the modifications of cellular metabolism induced by Notch1 upregulation in T-ALL. Previously, glutaminolysis inhibition has been proposed to synergize with anti-Notch therapies in T-ALL models. In this work, we report that Notch1 upregulation in T-ALL induced a change in the metabolism of the important amino acid glutamine, preventing glutamine synthesis through the downregulation of glutamine synthetase (GS). Downregulation of GS was responsible for glutamine addiction in Notch1-driven T-ALL both in vitro and in vivo. Our results also confirmed an increase in glutaminolysis mediated by Notch1. Increased glutaminolysis resulted in the activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway, a central controller of cell growth. However, glutaminolysis did not play any role in Notch1-induced glutamine addiction. Finally, the combined treatment targeting mTORC1 and limiting glutamine availability had a synergistic effect to induce apoptosis and to prevent Notch1-driven leukemia progression. Our results placed glutamine limitation and mTORC1 inhibition as a potential therapy against Notch1-driven leukemia.
- Published
- 2021
32. Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis
- Author
-
Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Fondation pour la Recherche Médicale, Fondation ARC pour la Recherche sur le Cancer, Université de Bordeaux, Conseil régional d'Aquitaine, Ministre de l'Enseignement Supérieur, de la Recherche et de l'Innovation (France), Bodineau, Clément, Tomé, Mercedes, Courtois, Sarah, Costa, Ana S. H., Sciacovelli, Marco, Rousseau, Benoit, Richard, Elodie, Vacher, Pierre, Parejo-Pérez, Carlos, Bessède, Emilie, Varon, Christine, Soubeyran, Pierre, Frezza, Christian, Murdoch, Piedad del S., Villar, Victor H., Durán, Raúl V., Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Fondation pour la Recherche Médicale, Fondation ARC pour la Recherche sur le Cancer, Université de Bordeaux, Conseil régional d'Aquitaine, Ministre de l'Enseignement Supérieur, de la Recherche et de l'Innovation (France), Bodineau, Clément, Tomé, Mercedes, Courtois, Sarah, Costa, Ana S. H., Sciacovelli, Marco, Rousseau, Benoit, Richard, Elodie, Vacher, Pierre, Parejo-Pérez, Carlos, Bessède, Emilie, Varon, Christine, Soubeyran, Pierre, Frezza, Christian, Murdoch, Piedad del S., Villar, Victor H., and Durán, Raúl V.
- Abstract
Glutamoptosis is the induction of apoptotic cell death as a consequence of the aberrant activation of glutaminolysis and mTORC1 signaling during nutritional imbalance in proliferating cells. The role of the bioenergetic sensor AMPK during glutamoptosis is not defined yet. Here, we show that AMPK reactivation blocks both the glutamine-dependent activation of mTORC1 and glutamoptosis in vitro and in vivo. We also show that glutamine is used for asparagine synthesis and the GABA shunt to produce ATP and to inhibit AMPK, independently of glutaminolysis. Overall, our results indicate that glutamine metabolism is connected with mTORC1 activation through two parallel pathways: an acute alpha-ketoglutarate-dependent pathway; and a secondary ATP/AMPK-dependent pathway. This dual metabolic connection between glutamine and mTORC1 must be considered for the future design of therapeutic strategies to prevent cell growth in diseases such as cancer.
- Published
- 2021
33. BRCA2 promotes DNA-RNA hybrid resolution by DDX5 helicase at DNA breaks to facilitate their repair‡
- Author
-
Agence Nationale de la Recherche (France), Institut National du Cancer (France), Ligue Nationale contre le Cancer (France), European Research Council, Ministerio de Economía y Competitividad (España), Fundación Vencer el Cancer, European Commission, Institut Curie, Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Asociación Española Contra el Cáncer, Ministerio de Economía, Industria y Competitividad (España), Fondation de France, Sessa, Gaetana, Gómez-González, Belén, Silva, Sonia, Pérez-Calero, Carmen, Beaurepere, Romane, Barroso, Sonia, Martineau, Sylvain, Martin, Charlotte, Ehlén, Åsa, Martínez, Juan S., Lombard, Bérangère, Loew, Damarys, Vagner, Stephan, Aguilera, Andrés, Carreira, Aura, Agence Nationale de la Recherche (France), Institut National du Cancer (France), Ligue Nationale contre le Cancer (France), European Research Council, Ministerio de Economía y Competitividad (España), Fundación Vencer el Cancer, European Commission, Institut Curie, Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Asociación Española Contra el Cáncer, Ministerio de Economía, Industria y Competitividad (España), Fondation de France, Sessa, Gaetana, Gómez-González, Belén, Silva, Sonia, Pérez-Calero, Carmen, Beaurepere, Romane, Barroso, Sonia, Martineau, Sylvain, Martin, Charlotte, Ehlén, Åsa, Martínez, Juan S., Lombard, Bérangère, Loew, Damarys, Vagner, Stephan, Aguilera, Andrés, and Carreira, Aura
- Abstract
The BRCA2 tumor suppressor is a DNA double-strand break (DSB) repair factor essential for maintaining genome integrity. BRCA2-deficient cells spontaneously accumulate DNA-RNA hybrids, a known source of genome instability. However, the specific role of BRCA2 on these structures remains poorly understood. Here we identified the DEAD-box RNA helicase DDX5 as a BRCA2-interacting protein. DDX5 associates with DNA-RNA hybrids that form in the vicinity of DSBs, and this association is enhanced by BRCA2. Notably, BRCA2 stimulates the DNA-RNA hybrid-unwinding activity of DDX5 helicase. An impaired BRCA2-DDX5 interaction, as observed in cells expressing the breast cancer variant BRCA2-T207A, reduces the association of DDX5 with DNA-RNA hybrids, decreases the number of RPA foci, and alters the kinetics of appearance of RAD51 foci upon irradiation. Our findings are consistent with DNA-RNA hybrids constituting an impediment for the repair of DSBs by homologous recombination and reveal BRCA2 and DDX5 as active players in their removal.
- Published
- 2021
34. A new interaction between BRCA2 and DDX5 promotes the repair of DNA breaks at transcribed chromatin
- Author
-
Asociación Española Contra el Cáncer, Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale contre le Cancer (France), European Research Council, Ministerio de Economía y Competitividad (España), European Commission, Gómez-González, Belén, Sessa, Gaetana, Carreira, Aura, Aguilera, Andrés, Asociación Española Contra el Cáncer, Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale contre le Cancer (France), European Research Council, Ministerio de Economía y Competitividad (España), European Commission, Gómez-González, Belén, Sessa, Gaetana, Carreira, Aura, and Aguilera, Andrés
- Abstract
In a recent report, we have revealed a new interaction between the BRCA2 DNA repair associated protein (BRCA2) and the DEAD-box helicase 5 (DDX5) at DNA breaks that promotes unwinding DNA-RNA hybrids within transcribed chromatin and favors repair. Interestingly, BRCA2–DDX5 interaction is impaired in cells expressing the BRCA2 missense variant found in breast cancer patients.
- Published
- 2021
35. C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation
- Author
-
Ministerio de Economía y Competitividad (España), Junta de Castilla y León, European Commission, Universidad Complutense de Madrid, Ministerio de Educación (España), Fundación BBVA, Fondation de France, Fondation ARC pour la Recherche sur le Cancer, Sequera, Celia, Bragado, Paloma, Manzano Figueroa, Sara, Arechederra, María, Richelme, Sylvie, Gutiérrez-Uzquiza, Álvaro, Sánchez, Aranzazu, Maina, Flavio, Guerrero Arroyo, María del Carmen, Porras, Almudena, Ministerio de Economía y Competitividad (España), Junta de Castilla y León, European Commission, Universidad Complutense de Madrid, Ministerio de Educación (España), Fundación BBVA, Fondation de France, Fondation ARC pour la Recherche sur le Cancer, Sequera, Celia, Bragado, Paloma, Manzano Figueroa, Sara, Arechederra, María, Richelme, Sylvie, Gutiérrez-Uzquiza, Álvaro, Sánchez, Aranzazu, Maina, Flavio, Guerrero Arroyo, María del Carmen, and Porras, Almudena
- Abstract
The complexity of hepatocellular carcinoma (HCC) challenges the identification of disease-relevant signals. C3G, a guanine nucleotide exchange factor for Rap and other Ras proteins, plays a dual role in cancer acting as either a tumor suppressor or promoter depending on tumor type and stage. The potential relevance of C3G upregulation in HCC patients suggested by database analysis remains unknown. We have explored C3G function in HCC and the underlying mechanisms using public patient data and in vitro and in vivo human and mouse HCC models. We found that C3G is highly expressed in progenitor cells and neonatal hepatocytes, whilst being down-regulated in adult hepatocytes and re-expressed in human HCC patients, mouse HCC models and HCC cell lines. Moreover, high C3G mRNA levels correlate with tumor progression and a lower patient survival rate. C3G expression appears to be tightly modulated within the HCC program, influencing distinct cell biological properties. Hence, high C3G expression levels are necessary for cell tumorigenic properties, as illustrated by reduced colony formation in anchorage-dependent and -independent growth assays induced by permanent C3G silencing using shRNAs. Additionally, we demonstrate that C3G down-regulation interferes with primary HCC tumor formation in xenograft assays, increasing apoptosis and decreasing proliferation. In vitro assays also revealed that C3G down-regulation enhances the pro-migratory, invasive and metastatic properties of HCC cells through an epithelial-mesenchymal switch that favors the acquisition of a more mesenchymal phenotype. Consistently, a low C3G expression in HCC cells correlates with lung metastasis formation in mice. However, the subsequent restoration of C3G levels is associated with metastatic growth. Mechanistically, C3G down-regulation severely impairs HGF/MET signaling activation in HCC cells. Collectively, our results indicate that C3G is a key player in HCC. C3G promotes tumor growth and progression
- Published
- 2020
36. Two antagonistic microtubule targeting drugs act synergistically to kill cancer cells
- Author
-
Université Grenoble Alpes, Institut National de la Santé et de la Recherche Médicale (France), Centre National de la Recherche Scientifique (France), Institut National du Cancer (France), Fondation ARC pour la Recherche sur le Cancer, European Commission, Ministerio de Economía y Competitividad (España), Netherlands Organization for Scientific Research, Peronne, Lauralie, Denarier, Eric, Rai, Ankit, Prudent, Renaud, Vernet, Audrey, Suzanne, Peggy, Ramírez-Ríos, Sacnicte, Michallet, Sophie, Guidetti, Mélanie, Vollaire, Julien, Lucena-Agell, Daniel, Ribba, Anne-Sophie, Josserand, Véronique, Coll, Jean-Luc, Dallemagne, Patrick, Díaz, José Fernando, Oliva, María A., Sadoul, Karin, Akhmanova, Anna, Andrieux, Annie, Lafanechère, Laurence, Université Grenoble Alpes, Institut National de la Santé et de la Recherche Médicale (France), Centre National de la Recherche Scientifique (France), Institut National du Cancer (France), Fondation ARC pour la Recherche sur le Cancer, European Commission, Ministerio de Economía y Competitividad (España), Netherlands Organization for Scientific Research, Peronne, Lauralie, Denarier, Eric, Rai, Ankit, Prudent, Renaud, Vernet, Audrey, Suzanne, Peggy, Ramírez-Ríos, Sacnicte, Michallet, Sophie, Guidetti, Mélanie, Vollaire, Julien, Lucena-Agell, Daniel, Ribba, Anne-Sophie, Josserand, Véronique, Coll, Jean-Luc, Dallemagne, Patrick, Díaz, José Fernando, Oliva, María A., Sadoul, Karin, Akhmanova, Anna, Andrieux, Annie, and Lafanechère, Laurence
- Abstract
Paclitaxel is a microtubule stabilizing agent and a successful drug for cancer chemotherapy inducing, however, adverse effects. To reduce the effective dose of paclitaxel, we searched for pharmaceutics which could potentiate its therapeutic effect. We screened a chemical library and selected Carba1, a carbazole, which exerts synergistic cytotoxic effects on tumor cells grown in vitro, when co-administrated with a low dose of paclitaxel. Carba1 targets the colchicine binding-site of tubulin and is a microtubule-destabilizing agent. Catastrophe induction by Carba1 promotes paclitaxel binding to microtubule ends, providing a mechanistic explanation of the observed synergy. The synergistic effect of Carba1 with paclitaxel on tumor cell viability was also observed in vivo in xenografted mice. Thus, a new mechanism favoring paclitaxel binding to dynamic microtubules can be transposed to in vivo mouse cancer treatments, paving the way for new therapeutic strategies combining low doses of microtubule targeting agents with opposite mechanisms of action.
- Published
- 2020
37. Targeting the stress-induced protein NUPR1 to treat pancreatic adenocarcinoma
- Author
-
Ligue Nationale contre le Cancer (France), Institut National du Cancer (France), Fondation de France, Institut National de la Santé et de la Recherche Médicale (France), Fondation ARC pour la Recherche sur le Cancer, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Diputación General de Aragón, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Alfonso Martín Escudero, National Natural Science Foundation of China, China Scholarship Council, Santofimia-Castaño, Patricia, Xia, Yi, Peng, Ling, Velázquez-Campoy, Adrián, Abian, Olga, Lan, Wenjun, Lomberk, Gwen, Urrutia, Raul, Rizzuti, Bruno, Soubeyran, Philippe, Neira, José L., Iovanna, Juan Lucio, Ligue Nationale contre le Cancer (France), Institut National du Cancer (France), Fondation de France, Institut National de la Santé et de la Recherche Médicale (France), Fondation ARC pour la Recherche sur le Cancer, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Diputación General de Aragón, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Alfonso Martín Escudero, National Natural Science Foundation of China, China Scholarship Council, Santofimia-Castaño, Patricia, Xia, Yi, Peng, Ling, Velázquez-Campoy, Adrián, Abian, Olga, Lan, Wenjun, Lomberk, Gwen, Urrutia, Raul, Rizzuti, Bruno, Soubeyran, Philippe, Neira, José L., and Iovanna, Juan Lucio
- Abstract
Cancer cells activate stress-response mechanisms to adapt themselves to a variety of stressful conditions. Among these protective mechanisms, those controlled by the stress-induced nuclear protein 1 (NUPR1 ) belong to the most conserved ones. NUPR1 is an 82-residue-long, monomeric, basic and intrinsically disordered protein (IDP), which was found to be invariably overexpressed in some, if not all, cancer tissues. Remarkably, we and others have previously showed that genetic inactivation of the Nupr1 gene antagonizes the growth of pancreatic cancer as well as several other tumors. With the use of a multidisciplinary strategy by combining biophysical, biochemical, bioinformatic, and biological approaches, a trifluoperazine-derived compound, named ZZW-115, has been identified as an inhibitor of the NUPR1 functions. The anticancer activity of the ZZW-115 was first validated on a large panel of cancer cells. Furthermore, ZZW-115 produced a dose-dependent tumor regression of the tumor size in xenografted mice. Mechanistically, we have demonstrated that NUPR1 binds to several importins. Because ZZW-115 binds NUPR1 through the region around the amino acid Thr68, which is located into the nuclear location signal (NLS) region of the protein, we demonstrated that treatment with ZZW-115 inhibits completely the translocation of NUPR1 from the cytoplasm to the nucleus by competing with importins.
- Published
- 2019
38. Increasing ergosterol levels delays formin-dependent assembly of F-actin cables and disrupts division plane positioning in fission yeast
- Author
-
Fondation ARC pour la Recherche sur le Cancer, Arbizzani, Federica, Rincón, Sergio A., Paoletti, Anne, Fondation ARC pour la Recherche sur le Cancer, Arbizzani, Federica, Rincón, Sergio A., and Paoletti, Anne
- Abstract
In most eukaryotes, cytokinesis is mediated by the constriction of a contractile acto-myosin ring (CR), which promotes the ingression of the cleavage furrow. Many components of the CR interact with plasma membrane lipids suggesting that lipids may regulate CR assembly and function. Although there is clear evidence that phosphoinositides play an important role in cytokinesis, much less is known about the role of sterols in this process. Here, we studied how sterols influence division plane positioning and CR assembly in fission yeast. We show that increasing ergosterol levels in the plasma membrane blocks the assembly of F-actin cables from cytokinetic precursor nodes, preventing their compaction into a ring. Abnormal F-actin cables form after a delay, leading to randomly placed septa. Since the formin Cdc12 was detected on cytokinetic precursors and the phenotype can be partially rescued by inhibiting the Arp2/3 complex, which competes with formins for F-actin nucleation, we propose that ergosterol may inhibit formin dependent assembly of F-actin cables from cytokinetic precursors.
- Published
- 2019
39. The telomeric Cdc13-Stn1-Ten1 complex regulates RNA polymerase II transcription
- Author
-
Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Ligue Nationale contre le Cancer (France), Fondation ARC pour la Recherche sur le Cancer, Generalitat Valenciana, Red Temática de Investigación Cooperativa en Cáncer (España), Calvo, Olga, Grandin, Nathalie, Jordán-Pla, Antonio, Miñambres, Esperanza, González-Polo, Noelia, Pérez-Ortín, José Enrique, Charbonneau, Michel, Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Ligue Nationale contre le Cancer (France), Fondation ARC pour la Recherche sur le Cancer, Generalitat Valenciana, Red Temática de Investigación Cooperativa en Cáncer (España), Calvo, Olga, Grandin, Nathalie, Jordán-Pla, Antonio, Miñambres, Esperanza, González-Polo, Noelia, Pérez-Ortín, José Enrique, and Charbonneau, Michel
- Abstract
Specialized telomeric proteins have an essential role in maintaining genome stability through chromosome end protection and telomere length regulation. In the yeast Saccharomyces cerevisiae, the evolutionary conserved CST complex, composed of the Cdc13, Stn1 and Ten1 proteins, largely contributes to these functions. Here, we report the existence of genetic interactions between TEN1 and several genes coding for transcription regulators. Molecular assays confirmed this novel function of Ten1 and further established that it regulates the occupancies of RNA polymerase II and the Spt5 elongation factor within transcribed genes. Since Ten1, but also Cdc13 and Stn1, were found to physically associate with Spt5, we propose that Spt5 represents the target of CST in transcription regulation. Moreover, CST physically associates with Hmo1, previously shown to mediate the architecture of S phase-transcribed genes. The fact that, genome-wide, the promoters of genes down-regulated in the ten1-31 mutant are prefentially bound by Hmo1, leads us to propose a potential role for CST in synchronizing transcription with replication fork progression following head-on collisions.
- Published
- 2019
40. Prothoracicotropic hormone modulates environmental adaptive plasticity through the control of developmental timing
- Author
-
Institut National de la Santé et de la Recherche Médicale (France), Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, European Research Council, National Institutes of Health (US), Ministerio de Economía y Competitividad (España), Shimell, M.J., Pan, X., Martín, Francisco A., Ghosh, A.C., Leopold, P., O’Connor, M.B, Romero, N.M, Institut National de la Santé et de la Recherche Médicale (France), Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, European Research Council, National Institutes of Health (US), Ministerio de Economía y Competitividad (España), Shimell, M.J., Pan, X., Martín, Francisco A., Ghosh, A.C., Leopold, P., O’Connor, M.B, and Romero, N.M
- Abstract
Adult size and fitness are controlled by a combination of genetics and environmental cues. In Drosophila, growth is confined to the larval phase and final body size is impacted by the duration of this phase, which is under neuroendocrine control. The neuropeptide prothoracicotropic hormone (PTTH) has been proposed to play a central role in controlling the length of the larval phase through regulation of ecdysone production, a steroid hormone that initiates larval molting and metamorphosis. Here, we test this by examining the consequences of null mutations in the Ptth gene for Drosophila development. Loss of Ptth causes several developmental defects, including a delay in developmental timing, increase in critical weight, loss of coordination between body and imaginal disc growth, and reduced adult survival in suboptimal environmental conditions such as nutritional deprivation or high population density. These defects are caused by a decrease in ecdysone production associated with altered transcription of ecdysone biosynthetic genes. Therefore, the PTTH signal contributes to coordination between environmental cues and the developmental program to ensure individual fitness and survival.
- Published
- 2018
41. Integrative visual omics of the white-rot fungus Polyporus brumalis exposes the biotechnological potential of its oxidative enzymes for delignifying raw plant biomass
- Author
-
Alliance Nationale pour les Sciences de la Vie et de la Santé (France), European Molecular Biology Laboratory, Fondation ARC pour la Recherche sur le Cancer, France Génomique, GenoScreen, Grand Luminy Technopôle, Institut National de la Recherche Agronomique (France), Institut Paoli-Calmettes, omicX, Conseil Régional Provence-Alpes-Côte d'Azur, Département des Bouches-du-Rhône, Ville de Marseille, Drula, Elodie [0000-0002-9168-5214], Rancon, Anaïs [0000-0002-6258-0755], Henrissat, Bernard [0000-0002-3434-8588], Hainaut, Matthieu [0000-0002-7567-657X], Ruiz-Dueñas, F. J. [0000-0002-9837-5665], Herpoël-Gimbert, Isabelle [0000-0001-5518-8969], Navarro, David [0000-0002-3266-8270], Grigoriev, Igor V. [0000-0002-3136-8903], Raouche, Sana [0000-0001-5937-4902], Rosso, Marie-Noëlle https://orcid.org/0000-0001-8317-7220, Drula, Elodie, Miyauchi, Shingo, Rancon, Anaïs, Henrissat, Bernard, Hainaut, Matthieu, Ruiz-Dueñas, F. J., Herpoël-Gimbert, Isabelle, Navarro, David, Grigoriev, Igor V., Zhou, Simeng, Raouche, Sana, Rosso, Marie-Noëlle, Alliance Nationale pour les Sciences de la Vie et de la Santé (France), European Molecular Biology Laboratory, Fondation ARC pour la Recherche sur le Cancer, France Génomique, GenoScreen, Grand Luminy Technopôle, Institut National de la Recherche Agronomique (France), Institut Paoli-Calmettes, omicX, Conseil Régional Provence-Alpes-Côte d'Azur, Département des Bouches-du-Rhône, Ville de Marseille, Drula, Elodie [0000-0002-9168-5214], Rancon, Anaïs [0000-0002-6258-0755], Henrissat, Bernard [0000-0002-3434-8588], Hainaut, Matthieu [0000-0002-7567-657X], Ruiz-Dueñas, F. J. [0000-0002-9837-5665], Herpoël-Gimbert, Isabelle [0000-0001-5518-8969], Navarro, David [0000-0002-3266-8270], Grigoriev, Igor V. [0000-0002-3136-8903], Raouche, Sana [0000-0001-5937-4902], Rosso, Marie-Noëlle https://orcid.org/0000-0001-8317-7220, Drula, Elodie, Miyauchi, Shingo, Rancon, Anaïs, Henrissat, Bernard, Hainaut, Matthieu, Ruiz-Dueñas, F. J., Herpoël-Gimbert, Isabelle, Navarro, David, Grigoriev, Igor V., Zhou, Simeng, Raouche, Sana, and Rosso, Marie-Noëlle
- Published
- 2018
42. Otx2 promotes granule cell precursor proliferation and Shh-dependent medulloblastoma maintenance in vivo
- Author
-
Fondation ARC pour la Recherche sur le Cancer, Canceropole PACA, El Nagar, Salsabiel, Chakroun, Almahdi, Le Greneur, Coralie, Figarella-Branger, Dominique, Di Meglio, Thomas, Lamonerie, Thomas, Billon, Nathalie, Fondation ARC pour la Recherche sur le Cancer, Canceropole PACA, El Nagar, Salsabiel, Chakroun, Almahdi, Le Greneur, Coralie, Figarella-Branger, Dominique, Di Meglio, Thomas, Lamonerie, Thomas, and Billon, Nathalie
- Abstract
The developmental gene OTX2 is expressed by cerebellar granule cell precursors (GCPs), a cell population which undergoes massive expansion during the early postnatal period in response to sonic hedgehog (Shh). GCPs are thought to be at the origin of most medulloblastomas, a devastating paediatric cancer that arises in the developing cerebellum. OTX2 is overexpressed in all types of medulloblastomas, except in Shh-dependent type 2 medulloblastomas, although it has GCPs as cell-of-origin. This has led to the current view that OTX2 is not involved in tumorigenesis of this subgroup. How OTX2 might contribute to normal or tumoral GCP development in vivo remains unresolved. Here, we have investigated, for the first time, the physiological function of this factor in regulating proliferation and tumorigenesis in the developing mouse cerebellum. We first characterized Otx2-expressing cells in the early postnatal cerebellum and showed that they represent a unique subpopulation of highly proliferative GCPs. We next performed in vivo loss-of-function analysis to dissect out the role of Otx2 in these cells and identified a novel, Shh-independent, function for this factor in controlling postnatal GCP proliferation and cerebellum morphogenesis. Finally, we addressed the function of Otx2 in the context of type 2 medulloblastomas by directing Shh-dependent tumour formation in Otx2+ cells of the developing cerebellum and assessing the effects of Otx2 ablation in this context. We unravel an unexpected, mandatory function for Otx2 in sustaining cell proliferation and long-term maintenance of these tumours in vivo, therefore bringing unpredicted insight into the mechanisms of type 2 medulloblastoma subsistence. Together, these data pinpoint, for the first time, a crucial Shh-independent role for Otx2 in the control of proliferation of normal and tumoral granule cell precursors in vivo and make it an attractive candidate for targeted therapy in Shh-dependent medulloblastomas
- Published
- 2018
43. The Saccharomyces cerevisiae telomeric Cdc13-Stn1-Ten1 complex regulates RNA pol II transcription
- Author
-
Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Generalitat Valenciana, Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Ligue Nationale contre le Cancer (France), Fondation ARC pour la Recherche sur le Cancer, Calvo, Olga, Grandin, Nathalie, Jordán-Pla, Antonio, Miñambres, Esperanza, González-Polo, Noelia, Pérez-Ortín, José Enrique, Charbonneau, Michel, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Generalitat Valenciana, Ministerio de Economía y Competitividad (España), Consejo Superior de Investigaciones Científicas (España), Ligue Nationale contre le Cancer (France), Fondation ARC pour la Recherche sur le Cancer, Calvo, Olga, Grandin, Nathalie, Jordán-Pla, Antonio, Miñambres, Esperanza, González-Polo, Noelia, Pérez-Ortín, José Enrique, and Charbonneau, Michel
- Abstract
In eukaryotes, specialized telomere protein complexes have an essential function in chromosome end protection and recruitment of telomerase to maintain telomere length constant. In the yeast Saccharomyces cerevisiae, these functions are taken in charge by the evolutionary conserved CST complex, composed of the Cdc13, Stn1 and Ten1 proteins. Here, we report the identification of genetic interactions between ten1 mutations and mutations in several genes coding for transcription regulators. Molecular assays confirmed that Ten1 is functionally linked to RNA pol II transcription. More precisely, the ten1-31 mutation caused a reduction in the occupancy of RNA pol II and the Spt5 elongation factor within transcribed genes. Moreover, CST physically associated with both Spt5 and the HMGB protein Hmo1. Very interestingly, we observed genome-wide that the promoters of genes down-regulated in the ten1-31 mutant are prefentially bound by Hmo1, which is known to mediate the architecture of RNA pol II S phase-transcribed genes. This, together with our finding that CST mutants need the Ctf18 and Mrc1 DNA replication checkpoints for survival, leads us to propose a working model in which CST, traveling with the replication fork, synchronizes transcription with replication fork progression following head-on collisions.
- Published
- 2018
44. High levels of histones promote whole-genome-duplications and trigger a Swe1WEE1-dependent phosphorylation of Cdc28CDK1
- Author
-
Ligue Nationale contre le Cancer (France), Ministerio de Economía y Competitividad (España), Fondation ARC pour la Recherche sur le Cancer, Junta de Andalucía, European Commission, Maya, Douglas [0000-0002-0669-6526], Peñate, Xenia [0000-0002-4117-888X], Geli, Vicent [0000-0002-4103-7462], Maya-Miles, Douglas, Peñate, Xenia, Sanmartín Olmo, Trinidad, Jourquin, Frederic, Muñoz-Centeno, Mari Cruz, Mendoza García, Manuel, Simon, Marie-Noelle, Chávez, Sebastián, Geli, Vicent, Ligue Nationale contre le Cancer (France), Ministerio de Economía y Competitividad (España), Fondation ARC pour la Recherche sur le Cancer, Junta de Andalucía, European Commission, Maya, Douglas [0000-0002-0669-6526], Peñate, Xenia [0000-0002-4117-888X], Geli, Vicent [0000-0002-4103-7462], Maya-Miles, Douglas, Peñate, Xenia, Sanmartín Olmo, Trinidad, Jourquin, Frederic, Muñoz-Centeno, Mari Cruz, Mendoza García, Manuel, Simon, Marie-Noelle, Chávez, Sebastián, and Geli, Vicent
- Abstract
Whole-genome duplications (WGDs) have played a central role in the evolution of genomes and constitute an important source of genome instability in cancer. Here, we show in Saccharomyces cerevisiae that abnormal accumulations of histones are sufficient to induce WGDs. Our results link these WGDs to a reduced incorporation of the histone variant H2A.Z to chromatin. Moreover, we show that high levels of histones promote Swe1WEE1 stabilisation thereby triggering the phosphorylation and inhibition of Cdc28CDK1 through a mechanism different of the canonical DNA damage response. Our results link high levels of histones to a specific type of genome instability that is quite frequently observed in cancer and uncovers a new mechanism that might be able to respond to high levels of histones.
- Published
- 2018
45. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
- Author
-
Institut National du Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, National Institute on Drug Abuse (US), Théry, Clotilde, Yáñez-Mó, María, Zuba-Surma, Ewa K., Institut National du Cancer (France), Agence Nationale de la Recherche (France), Fondation ARC pour la Recherche sur le Cancer, National Institute on Drug Abuse (US), Théry, Clotilde, Yáñez-Mó, María, and Zuba-Surma, Ewa K.
- Abstract
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (>MISEV>) guidelines for the field in 2014. We now update these >MISEV2014> guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
- Published
- 2018
46. Endophilin, Dynamin & Actin: a cocktail required for efficient scission in clathrin-independent endocytosis of Shiga toxin
- Author
-
Institut Curie, Renard, Henri-François, Journées Jeunes Chercheurs of Fondation ARC, Institut Curie, Renard, Henri-François, and Journées Jeunes Chercheurs of Fondation ARC
- Published
- 2013
47. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein–protein interactions
- Author
-
Ministerio de Educación y Cultura (España), Commissariat à l'Ènergie Atomique et aux Ènergies Alternatives (France), Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, Électricité de France, Vidal, Antonio E., Boiteux, Serge, Hickson, Ian D., Radicella, J. Pablo, Ministerio de Educación y Cultura (España), Commissariat à l'Ènergie Atomique et aux Ènergies Alternatives (France), Centre National de la Recherche Scientifique (France), Fondation ARC pour la Recherche sur le Cancer, Électricité de France, Vidal, Antonio E., Boiteux, Serge, Hickson, Ian D., and Radicella, J. Pablo
- Abstract
The major human AP endonuclease APE1 (HAP1, APEX, Ref1) initiates the repair of abasic sites generated either spontaneously, from attack of bases by free radicals, or during the course of the repair of damaged bases. APE1 therefore plays a central role in the base excision repair (BER) pathway. We report here that XRCC1, another essential protein involved in the maintenance of genome stability, physically interacts with APE1 and stimulates its enzymatic activities. A truncated form of APE1, lacking the first 35 amino acids, although catalytically proficient, loses the affinity for XRCC1 and is not stimulated by XRCC1. Chinese ovary cell lines mutated in XRCC1 have a diminished capacity to initiate the repair of AP sites. This defect is compensated by the expression of XRCC1. XRCC1, acting as both a scaffold and a modulator of the different activities involved in BER, would provide a physical link between the incision and sealing steps of the AP site repair process. The interaction described extends the coordinating role of XRCC1 to the initial step of the repair of DNA abasic sites.
- Published
- 2001
48. Components of the human SWI/SNF complex are enriched in active chromatin and are associated with the nuclear matrix
- Author
-
European Molecular Biology Laboratory, Human Frontier Science Program, Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale contre le Cancer (France), Ministère de la Recherche et des Technologies (France), Reyes, José C., Muchardt, Christian, Yaniv, Moshe, European Molecular Biology Laboratory, Human Frontier Science Program, Fondation ARC pour la Recherche sur le Cancer, Ligue Nationale contre le Cancer (France), Ministère de la Recherche et des Technologies (France), Reyes, José C., Muchardt, Christian, and Yaniv, Moshe
- Abstract
Biochemical and genetic evidence suggest that the SWI/SNF complex is involved in the remodeling of chromatin during gene activation. We have used antibodies specific against three human subunits of this complex to study its subnuclear localization, as well as its potential association with active chromatin and the nuclear skeleton. Immunofluorescence studies revealed a punctate nuclear labeling pattern that was excluded from the nucleoli and from regions of condensed chromatin. Dual labeling failed to reveal significant colocalization of BRG1 or hBRM proteins with RNA polymerase II or with nuclear speckles involved in splicing. Chromatin fractionation experiments showed that both soluble and insoluble active chromatin are enriched in the hSWI/SNF proteins as compared with bulk chromatin. hSWI/SNF proteins were also found to be associated with the nuclear matrix or nuclear scaffold, suggesting that a fraction of the hSWI/SNF complex could be involved in the chromatin organization properties associated with matrix attachment regions.
- Published
- 1997
49. The mosaic genome of warm-blooded vertebrates
- Author
-
Fondation ARC pour la Recherche sur le Cancer, Salinas, Julio [0000-0003-2020-0950], Bernardi, G., Olofsson, Birgitta, Filipski, J., Zerial, Marino, Salinas, Julio, Cuny, Gerard, Meunier-Rotival, Michele, Rodier, Francis, Fondation ARC pour la Recherche sur le Cancer, Salinas, Julio [0000-0003-2020-0950], Bernardi, G., Olofsson, Birgitta, Filipski, J., Zerial, Marino, Salinas, Julio, Cuny, Gerard, Meunier-Rotival, Michele, and Rodier, Francis
- Abstract
Most of the nuclear genome of warm-blooded vertebrates is a mosaic of very long (>>200 kilobases) DNA segments, the isochores; these isochores are fairly homogeneous in base composition and belong to a small number of major classes distinguished by differences in guanine-cytosine (GC) content. The families of DNA molecules derived from such classes can be separated and used to study the genome distribution of any sequence which can be probed. This approach has revealed (i) that the distribution of genes, integrated viral sequences, and interspersed repeats is highly nonuniform in the genome, and (ii) that the base composition and ratio of CpG to GpC in both coding and noncoding sequences, as well as codon usage, mainly depend on the GC content of the isochores harboring the sequences. The compositional compartmentalization of the genome of warm-blooded vertebrates is discussed with respect to its evolutionary origin, its causes, and its effects on chromosome structure and function.
- Published
- 1985
50. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia
- Author
-
Marie Sebert, Stéphanie Gachet, Thierry Leblanc, Alix Rousseau, Olivier Bluteau, Rathana Kim, Raouf Ben Abdelali, Flore Sicre de Fontbrune, Loïc Maillard, Carèle Fedronie, Valentine Murigneux, Léa Bellenger, Naira Naouar, Samuel Quentin, Lucie Hernandez, Nadia Vasquez, Mélanie Da Costa, Pedro H. Prata, Lise Larcher, Marie de Tersant, Matthieu Duchmann, Anna Raimbault, Franck Trimoreau, Odile Fenneteau, Wendy Cuccuini, Nathalie Gachard, Nathalie Auger, Giulia Tueur, Maud Blanluet, Claude Gazin, Michèle Souyri, Francina Langa Vives, Aaron Mendez-Bermudez, Hélène Lapillonne, Etienne Lengline, Emmanuel Raffoux, Pierre Fenaux, Lionel Adès, Edouard Forcade, Charlotte Jubert, Carine Domenech, Marion Strullu, Bénédicte Bruno, Nimrod Buchbinder, Caroline Thomas, Arnaud Petit, Guy Leverger, Gérard Michel, Marina Cavazzana, Eliane Gluckman, Yves Bertrand, Nicolas Boissel, André Baruchel, Jean-Hugues Dalle, Emmanuelle Clappier, Eric Gilson, Ludovic Deriano, Sylvie Chevret, François Sigaux, Gérard Socié, Dominique Stoppa-Lyonnet, Hugues de Thé, Christophe Antoniewski, Dominique Bluteau, Régis Peffault de Latour, Jean Soulier, Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génomes, biologie cellulaire et thérapeutiques (GenCellDi (U944 / UMR7212)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), AP-HP Hôpital universitaire Robert-Debré [Paris], Recherche clinique appliquée à l'hématologie (URP_3518), Intégrité du génome, immunité et cancer - Genome integrity, Immunity and Cancer, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Limoges, Institut Gustave Roussy (IGR), Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hématopoïèse normale et pathologique : émergence, environnement et recherche translationnelle [Paris] ((UMR_S1131 / U1131)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre d'Ingénierie génétique murine - Mouse Genetics Engineering Center (CIGM), Institut Pasteur [Paris] (IP), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpitaux universitaires Est parisien [AP-HP], CHU Bordeaux [Bordeaux], Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Rouen, Normandie Université (NU), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Hôpital de la Timone [CHU - APHM] (TIMONE), CIC NECKER BT (CIC 1416), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Collège de France (CdF (institution)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL), This study received support from the European Research Council (ERC) Consolidator Grant to J.S. (CEVAL-311660), the FP7 Eurofancolen program (HEALTH-F5-2012-305421), the ANR program PACRI (Projet alliance parisienne des instituts de recherche en cancérologie), the CONECT-AML (Collaborative Network for Children and Teenagers with Acute Myeloid Leukemia) program supported by a grant from the Institut National du Cancer (INCa), Fondation ARC, Ligue nationale contre le cancer, and Laurette Fugain (INCa-ARC-LIGUE_11905) to J.S. and C.A., and the Association Française pour la Maladie de Fanconi (AFMF) grants 'Histoire naturelle de la maladie de Fanconi' to R.P.L. and J.S., 'Modélisation de la transformation leucémique dans la maladie de Fanconi' to D.B., and 'Cribles fonctionnels à haut débit de gènes modificateurs de la maladie de Fanconi' to C.G. M.S. was supported by the AVIESAN-INCa Program 'Formation à la Recherche Translationnelle,' and A.R. by a grant from the Fondation ARC. The work in E.G.’s lab is supported by Fondation ARC and ANR Telochrom. The work in L.D.’s lab is supported by INCa (PLBIO16-181) and ERC (310917)., ANR-11-PHUC-0002,PACRI,Alliance Parisienne des Instituts de Recherche en Cancérologie(2011), European Project: 311660,EC:FP7:ERC,ERC-2012-StG_20111109,CEVAL(2013), and European Project: 305421,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,EUROFANCOLEN(2013)
- Subjects
MDM4 ,Fanconi anemia ,precision medicine ,[SDV]Life Sciences [q-bio] ,Genetics ,leukemia ,clonal hematopoiesis ,Molecular Medicine ,Cell Biology ,TP53 ,mutational signature ,genomic instability ,BRCA2 - Abstract
International audience; Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated translocations driving copy-number alterations. Half the patients developed chromosome 1q gain, driving clonal hematopoiesis through MDM4 trisomy downmodulating p53 signaling later followed by secondary acute myeloid lukemia genomic alterations. Functionally, MDM4 triplication conferred greater fitness to murine and human primary FA HSPCs, rescued inflammation-mediated bone marrow failure, and drove clonal dominance in FA mouse models, while targeting MDM4 impaired leukemia cells in vitro and in vivo. Our results identify a linear route toward secondary leukemogenesis whereby early MDM4-driven downregulation of basal p53 activation plays a pivotal role, opening monitoring and therapeutic prospects.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.